Abstract. The non-coding RNAs are new players in cellular and molecular biology. Indeed, quantitative and functional non-coding RNA has long been underestimated. There is a great diversity and it seems that much of the genome is transcribed into RNA, while only 1.2% of DNA information is translated into proteins. Non-coding RNA has been categorized according to different specifications so large non-coding RNA includes RNA with 300 to more than 10,000 bp. In this study, we propose a new non-coding RNA named B2 discovered by differential display. B2 is a nuclear RNA which is 51,011 bp long with no significant open reading frame. This RNA has a continuous homology with the genomic DNA of the HEF1/ NEDD9/Cas-L gene located on 6p24-p25. This homology has enabled us to characterize its structure by choosing overlapping fragments to perform several RT-PCRs. B2 RNA extends from 10 kb upstream of exon 1 of the HEF1 gene on the 5' end to exon 4 HEF1 on the 3' end. In addition, a strategic choice of PCR primers enabled us to determine the location of B2 in the subcellular compartment and then realtime PCR revealed overexpression of B2 and HEF1 in certain tissues such as thymus, cervix, liver, and spleen (among the 20 tissues analysed). B2 seems especially interesting in that it can regulate apoptosis and cell proliferation by modulating HEF1. In addition, the fact that cytostatic treatments can induce B2 reinforces the interest in this new potential target in the development of anticancer treatments. These results show that this novel non-coding RNA is an attractive target.
Introduction
The non-small-cell lung carcinomas (NSCLC) represent 80% (1) of all cases of lung cancer but remain very resistant to all therapies currently in use such as chemotherapy, radiotherapy and surgery (2) . These therapies focus on fast proliferating cells but such lung cancers have a slow doubling time, sometimes extending for many months, which explains their chemoresistance. In this context, a new approach would be to develop an appropriate strategy with a greater specificity for cancer cells and a lower toxicity for normal cells thus halting the slowly developing tumour. With this objective, we investigated the screening of original natural or synthetic chemical compounds to find new molecules with innovative mechanisms of action. Cytostatic substances, that induce the arrest of NSCLC cells in the G1-phase of the cycle and then cell death through the apoptosis pathway, should be considered as potential candidates. These selected compounds must also show low toxicity and marked antitumour activity confirmed by good results in vivo on nude mice xenografts. Two synthetic molecules, VT1 and A190, have been shown to exhibit all these activities and have already been patented by our laboratory. We have shown in our earlier studies on the NSCLC-N6 cell line that these substances trigger the overexpression of many genes involved in the arrest of G1 proliferation (3) . Using the differential display technique and the NSCLC cell line (NSCLC-N6), a large RNA, named B2, was identified and located on the human chromosome 6 at the p24-p25 locus. B2 has no significant ORF (http://www. ncbi.nlm.nih.gov/gorf/gorf.html) and one very interesting feature is that it overlaps the HEF1 gene (4) . HEF1 belongs to a family of docking adapter proteins, including p130
Cas and Efs, named the Cas family (5, 6) . The gene HEF1 was discovered in 1996 but, in recent years, an increasing number of studies concerning this gene have been published. HEF1 is involved in many different cellular functions, including migration, mitosis, differentiation and apoptosis (7, 8 HEF1 is a ubiquitous gene, present in many healthy tissues as well as in cell lines at different levels of expression. It is particularly expressed in lung tissue and pulmonary cell lines (5, 6, 9) .
The transcription of HEF1 is lower in phase G1 and increases in phase S reaching a maximum during phase G2/M. During the cell cycle, the p105 HEF1 protein and p115 HEF1 , its phosphorylated form, present in phase G1, are cleaved by caspases into p55 HEF1 and p65 HEF1 in the G2/M phase (6) . Moreover, HEF1 is concentrated in the centrosome and stimulates RhoA and Aurora A, two enzymes whose activation/inactivation is essential in the whole mitosis process (10). Dadke and colleagues (19) have shown that HEF1 is essential, in a very precise quantity, for the cell cycle to progress. The protein depletion resulting from RNA interference, as well as its overabundance, trigger apoptosis. Lastly, during mitosis, p55
HEF1 associates with the mitotic spindle and decreases suddenly at the end of mitosis as a result of proteosomal degradation.
The major role of HEF1 in the apoptosis process was first revealed by Law and colleagues (5). They induced HEF1 over-expression and showed that the cell cycle was blocked in the G1 phase. At the same time, they detected a new form of HEF1 protein, the p28 HEF1 . This protein is derived from the split of the protein p65 HEF1 by caspases 3 and/or 7. It leads to cell death by destabilizing the focal adhesion site and stimulating anoikis. To date, the pro-apoptotic activity of HEF1 has been fully demonstrated and closely linked with the presence of this p28
HEF1 protein in the cell during HEF1 overexpression (11) .
In the present study, we show that the RNA B2, initially isolated through differential display, has a size of at least 51,011 bp and partially overlaps the HEF1 gene. Furthermore, 10 kb of its sequences are located upstream of exon 1 of HEF1. We also report that B2 has all the structural characteristics of a regulator 'large ncRNA'.
Materials and methods
Cell lines and cultures. Two cell lines were used in this study, A549 and NSCLC-N6 (L16), originating from an adenocarcinoma and an epidermoid lung cancer, respectively. The NSCLC-N6 (L16) is a cell line derived from a human nonsmall cell lung carcinoma of a previously untreated patient (moderately differentiated classified as T2N0M0) (12) . The A549 line was obtained from ATCC (reference CCL-185) (13) and is known to have a wild-type p53 gene while NSCLC-N6 has a mutant p53 gene, so it is very close to tumours in situ.
These cell lines were cultured in Roswell Park Memorial Institute (RPMI)-1640 enriched with 100 IU of penicillin and 100 μg/ml of streptomycin, 2 mM of glutamine and 5% foetal bovine serum. Cell culture plates were maintained in humidified incubators at 37˚C in a 5% CO 2 atmosphere. L16 has a cell doubling time of 48 h in vitro, and A549 has a 24 h doubling time.
Extraction of total, nuclear and cytoplasmic RNA. Total RNA was extracted from NSCLC-N6 and/or A549 cell lines using Trizol ® Reagent (Invitrogen, CA, USA) and chloroform according to the supplier's recommendations. Cell extracts were centrifuged at 12,000 x g for 15 min at 4˚C. The aqueous phase containing RNA was transferred to a fresh tube. An equal volume of 70% ethanol was added to the aqueous phase and mixed by vortexing. Then, samples were transferred to an RNA spin cartridge supplied with the Trizol ® plus RNA Purification Kit (PureLink™ Micro-to-Midi™ Total RNA Purification System, Invitrogen, Applied Biosystems) in order to remove DNA contamination. Then RNAs were eluted with RNase-free water.
The quality and concentration of purified RNAs were assessed using UV absorbance at 260/280 nm and samples were run on 1% agarose gel in order to check their quality. RNAs were stored at -80˚C.
To separate nuclear and cytoplasmic RNAs, some steps were added before the same extraction was carried out. Cells were washed with cold PBS and removed without trypsin and centrifuged for 5 min at 1,000 g. They were resuspended with a lysis buffer (Tris-Cl 50 mM pH 8.0, NaCl 100 mM, MgCl 2 5 mM and 0.5% nonidet P-40) and incubated for a few minutes on ice. Extracts were centrifuged for another 5 min at 13,000 g. Supernatant was collected and pellets were washed twice with PBS. SDS 20% was added to each fraction (supernatant and pellet) and mixed thoroughly by shaking or vortexing. Proteinase K (20 mg/ml) was added and the mix was incubated for 15 min at 37˚C.
DNase treatment.
To remove genomic DNA prior to reverse transcription PCR, Turbo™ DNase (Ambion) was used. If the RNA concentration was >200 μg/ml, samples were diluted to 10 μg nucleic acid/50 μl. The 10X turbo DNase buffer was added to sample to a 1X final concentration. Next, 2 U of turbo DNase was added to 10 μg RNA in a 50 μl reaction. Samples were incubated at 37˚C for 30 min. Then DNase Inactivation Reagent was added, the mix was incubated for 2 min then centrifuged at 10,000 x g for 1.5 min. The supernatant, which contained RNA, was transferred to fresh tubes.
RT-PCR.
RT was carried out with 1 μg of RNA in 10 μl with 0.125 μg/μl random primers and RNase-free water. This mixture was denatured at 65˚C for 10 min then kept on ice. Subsequently, it was completed to a final volume of 25 μl with a mix containing 8 mM of dNTP mix, 1X of M-MLV 5X reaction buffer, 25 units of recombinant RNasin ribonuclease inhibitor (Promega), and 200 units of M-MLV RT (Promega) and completed with RNase-free water. In order to check whether samples were contaminated by genomic DNA, the same mix was made with RNA without the reverse transcriptase. Following this step, samples were incubated for 2 h at 37˚C. cDNAs were stored at -20˚C. After reverse transcription, cDNAs were used as a template for specific PCR.
B2 was discovered as a 185-bp fragment during RT differential display analysis in NSCLC-N6 cells (4, 14) . In order to characterize the 5' and 3' ends, RACE-PCR was first applied. Then DNA homology with the human chromosome 6 (GenBank No. AL 136139.6 and AL 139807.6 sequences) was exploited to perform RT-PCR. Primers were chosen so that two contiguous amplicons overlapped by at least 100-150 bp ( Fig. 1 ). All primers were designed using the Primer3 software (http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi).
Among all the B2 primers, B2-Si3 (Table I) matched the genomic sequence located between exons 2 and 3 of the HEF1 gene and B2-Ex1-4 matched 4,000 bp upstream of the HEF1 exon 1. Both were used to assess tissue expression and subcellular location. HEF1 Exon5 primers (Table I) were used to assess HEF1 expression on the Firstchoice Panel ® , ß2-M-INT and ß2-M-EX were used as controls for ß2-microglobulin amplification. These primer pairs were as follows, left B2-M-INT matched on the junction of the genomic sequence before exon 2 and exon 2 of the gene were included, and right B2-M-INT on the junction of the genomic sequence before exon 3 and exon 3 were included. They were employed for specific nuclear amplification of ß2-microglobulin RNA.
Left ß2-M-EX matched on the junction exon 1-exon 2 and right ß2-M-EX on the junction exon 3-exon 4. They were used for cytoplasmic and nuclear amplification of ß2-microglobulin RNA.
The PCR mix, consisting of 1X final of CoralLoad PCR buffer (Quiagen), 200 μM of each dNTP, 0.5 μM of right Primer, 0.5 μM of left Primer and 2.5 units/reaction of Taq DNA polymerase (Quiagen) was in a final volume of 25 μl. The amplifications were performed with the following protocol, 3 min at 94˚C for initial denaturation then 39 cycles of amplification (60 sec at 94˚C, 60 sec at 60˚C for primer annealing, 60 sec at 72˚C for elongation), and 7 min at 72˚C for final elongation. PCR products were analysed on 1% agarose gels stained with ethidium bromide (BET).
Race-PCR. The first step of this experiment consisted of a specific reverse transcription. It was achieved from tRNA extracted from A549 and L16. RNA (1 μg) was used with 1 μM of a specific primer (sequence) in 8.5 μl final volume. The mix was denatured for 10 min at 65˚C in a thermocycler. Then, the 5X reaction buffer (Promega), dNTPs (10 mM), 20 IU RNase inhibitor (Promega), 100 mM DDT, 200 IU MMLV RT in 20 μl final volume were added and incubated at 37˚C for 50 min, then 5 min at 70˚C. In the second step, a poly C was added to the 3' end. The reaction buffer 5X, dCTP 2 mM and 10 U/μl were added to the previous mix and incubated for 15 min at 37˚C and then at 70˚C for 10 min. The third step is named anchored PCR. It is a normal PCR Table I . Characteristics of the probes used. Then these 20 normal tissues were tested in real-time PCR. B2 and HEF1 amplifications were carried out following the instructions of the manufacturer of SYBR Green PCR mix (Applied Biosystems) on the ABI Prism ® Sequence Detection System 7300. The primers were designed using Primer 3 (as described above). For the gene HEF1, the primers were chosen on two different exons (1 and 2) to be sure of no interference between the amplifications of HEF1 and B2. The primer sequences were HEF1, forward 5'-CGCT GCCGAAATGAATAT-3', reverse 5'-CCCTGTGTTCTGCT CTATGACG-3'; B2, forward 5'-ATTCCCTTGGATCTTGC CTT-3', reverse 5'-CGTGAGGTCTGCCACTAC-3'. The relative expression was normalized with ß-actin added to each gene, forward 5'-ATTCCCTTGCCTTCTTGGAT-3', reverse 5'-CGTGAGGTCTGCCACTACAG-3'. A control sample was used for each PCR to check the genomic DNA contamination of the cDNA template. The results were analysed using GenAmp 7300 SDS (Applied Biosystems).
Results

B2 RNA is at least 50 kb.
From the 185 bp long initial fragment, we carried out as many as 117 RT-PCR (sequences not shown) to characterize the whole sequence of the B2 RNA. Each amplicon was a 1-kb fragment and overlapped the previous and the next over at least 100 to 150 bp (Fig. 1) .
To date, considering all the fragments joined together, B2 spreads over at least 51,011 bp. It shows a total homology with the region 6p24-p25 of the human genome without any interruption. So it is formed with a single large exon.
B2 overlaps one part of the HEF1 gene, 10 kb match upstream of the exon 1 HEF1 and the last 40,000 bp spread from exon 1 to exon 4 of HEF1 (Fig. 2) . No significant ORF was identified in the whole sequence. Finally, the 5' end is defined. The sequence was published in Genbank, GQ497714.
B2 is a nuclear RNA. RT-PCR was performed on both nuclear and cytoplasmic RNAs. B2-Si3 as well as B2-EX-1 primers show amplification only on the nuclear RNA extract (Fig. 3) . B2-Si3 lies on the initial differential display located in the genomic sequence between exons 2 and 3 of the HEF1 gene but B2-EX4-1 matches the part upstream of exon 1 of HEF1, thus ruling out any interference with HEF1 mRNA. We have shown only the result with B2-EX4-1 because it is the same result.
Then RT-PCR was carried out with ß2-M-EX and ß2-M-INT primers on the same RNA extracts and the same cDNA. As might be expected, PCR amplification with ß2-M-INT was possible only on the nuclear RNA extract. This experiment, with the DNase treatment, confirms that nuclear RNA could actually be amplified in our extracts. Moreover, it also confirms that no nuclear contaminants were present in the cytoplasmic RNA fraction. With ß2-M-EX, PCR fragments were present both in the cytoplasmic and in the nuclear fraction because of the mRNA maturation that occurred in the nuclear compartment. Moreover, these latter primers enabled us to validate the RT step.
B2 RNA is as ubiquitous as the HEF1 gene. As B2 overlaps the HEF1 gene, we were interested in the relation between these two genes. More precisely, we investigated whether B2 and HEF1 were expressed in the same tissues. To test this, we chose to use the same commercial RNA panel that had been employed in a recent study on HEF1 (9) . So additional RT-PCR was performed with B2-Si3 and B2-EX1-4 primers. Each primer pair was tested on all 20 RNA extracts.
The expression of B2 RNA could be amplified in all normal tissues tested, such as for HEF1. The expression of these two genes were analysed with real-time PCR.
Quantification of B2 RNA and the HEF1 gene. As these 2 genes could be amplified in the 20 tissues tested, we investigated this directly using quantitative RT-PCR to analyse B2 and HEF1 expression in mRNAs prepared from 20 human tissues (Fig. 4) . HEF1 was most abundant in adipose, lung, cervix, liver and spleen and was detected at lower levels in the other tissues while B2 was most abundant in thymus, adipose, cervix, liver and spleen and was detected at lower levels in the other tissues (Table II) . These results are consistent with the study of Golemis et al (9) .
Discussion
Since the sequencing of the entire genome, we know that the transcriptome is much bigger than had previously been supposed. Particularly, in recent years numerous studies have shown the importance of small non-coding RNAs such as miRNA, small nuclear and nucleolar RNAs, in the regulation of gene expression. However, a new class of non-coding RNAs has also now emerged which comprises RNAs of several thousand bp. Most of these 'large RNAs' are not spliced and 
are at least 10 kb in size. Their function is not yet clear but some are involved in the regulation of the expression of adjacent genes. Among the best known is Air, a non-coding unspliced RNA of 108 kb which acts as the 'silencer' for three genes coding for proteins of the igf2r cluster (15) . Another is NTT, an RNA of 17 kb situated in 6q23-q24 next to the receptor Á of interferon, whose expression it regulates in CD4 + cells. Finally, there is Xist, a nuclear RNA of 17 kb which is involved in the transcriptional silencing of one of the two X chromosomes in the female embryo (16) .
The present study revealed a new large non-coding RNA, called B2, which is 51 kb long. It is nuclear, has no open reading frame and is found in the p24-p25 region of chromosome 6. It is particularly interesting because it presents a total and continuous homology with genomic DNA, and thus consists of one large exon that overlaps the HEF1 gene from exon 4 to >10,000 bp upstream of exon 1. In addition, we have compared the tissue expression of B2 and HEF1 in 20 RNAs of healthy tissues. Our results show that these two molecular targets are expressed in all the healthy tissues of the panel. However, HEF1 is overexpressed in adipose, spleen, cervix, liver, and lung. Moreover, when the expression of B2 is weaker, as in liver, there is an overexpression of HEF1. These results are in agreement with those published by Golemis and co-workers who showed an overexpression of HEF1 in lung (9) . B2, however, is overexpressed in adipose, spleen, cervix, liver and thymus (Fig. 4) . In fact, in the thymus, B2 is greatly overexpressed compared to HEF1. Collectively, the results show that overexpression of B2 leads to the repression of the HEF1 gene, as observed in the thymus, adipose, and spleen. Conversely, when B2 is weakly expressed, HEF1 is overexpressed as seen in the lung and kidney. These results confirm a link between the overexpression of B2 and the repression of HEF1, which implies that the non-coding RNA B2 regulates the HEF1 gene.
This could occur by numerous mechanisms, identified to varying degrees in previous studies. Among the best known is transcriptional interference. This results from a strong promoter acting on a weaker promoter located downstream and thus affects two genes close together (17) . Another mechanism can explain this regulation of HEF1 by B2; due to its nuclear location and large size, B2 can induce a loop in the chromatin enabling the repression of HEF1. Such chromatin loops have already been suggested to explain how much ncRNA takes part in the phenomenon of higher-order chromatin silencing (17) . Alternatively, the transcription of such a large RNA could simply enable all the transcription factors to be sequestered thus preventing gene HEF1 transcription (17) . Other hypotheses are also feasible; B2 is a non-coding nuclear RNA which could form an RNA/DNA triple helix during the transcription of the RNA of HEF1 thus blocking it as has already been shown (17) . The final hypothesis to be considered here is that B2 acts as an RNA precursor of miRNA. In fact, according to one study, H19 was one of the first non-coding RNAs to be identified and has recently been described as a precursor of miRNA (18) . As B2 RNA overlaps several exons of the HEF1 gene, it seems possible that B2 could induce miRNA directed against HEF1 mRNA. Moreover, bioinformatic analysis shows that the sequence of the B2 gene can generate numerous sequences typical of miRNA. These sequences would be recognized and cleaved into pre-miRNA by Drosha in the nuclear compartment then transferred by exportin 5 into the cytoplasm where the Dicer complex would transform these pre-miRNA into miRNA (18) .
The HEF1 gene is known for its involvement in the control of cell growth, in apoptosis and in cell motility through its interaction with cellular adhesion sites and the mitotic spindle (5, 19 (20) . The C-terminal region of this p28 HEF1 seems to be responsible for the pro-apoptotic activity of HEF1. In fact, p28
HEF1 favours the cleavage of Focal Adhesion Kinase (FAK) leading to apoptosis (11) .
Cell proliferation, motility and growth are the three target areas of anticancer chemotherapy. In this approach, our aim was to demonstrate that HEF1 and B2 are involved in halting proliferation by inducing apoptosis in the anticancer chemotherapy of lung cancer. The work of Moreau et al (20) has highlighted the antitumour effect of the cytostatic molecule A190 on nude mice xenografted by non-small cell lung carcinomas.
The results that we have obtained on the two lung cell lines A549 and L16 during treatment with A190 confirm the existence of HEF1 gene regulation by B2 RNA.
A190 induces cell apoptosis at the same time as it increases the expression of both HEF1 and B2 RNA. This overexpression occurs after 60 h of treatment and falls dramatically after 70 h. If non-coding B2 RNA acts as a precursor of miRNA, it would enable the production of miRNA directed against HEF1 mRNA, explaining the sudden drop in the level of expression. The decrease in HEF1 mRNA would lead to a lack of HEF1 protein which would fall below the minimal threshold required for the cell cycle to progress and apoptosis would be triggered.
The team of Golemis (7, 8) has demonstrated that the normal progression of the cell cycle requires a precise quantity of the HEF1 protein. This must lie between an upper and a lower limit, thus three possible situations can occur. If there is the correct quantity of HEF1 protein in the cell, the truncated form p55 HEF1 contributes to the normal cell cycle and mitosis can take place. However, if there is excess HEF1, above the upper limit, then the p65 HEF1 form, also in excess, is cleaved into p28 HEF1 which initiates apoptosis. Similarly, if there is insufficient HEF1, below the lower limit, the cell cycle will be irreversibly stopped in the very early stages of mitosis.
The latter situation would be applicable during treatment of cells A549 and L16. This would explain how the molecule A190 could trigger apoptosis even in the absence of p28 HEF1 which has never been detected by Western blotting (data not shown).
There remains a great deal to discover about large ncRNAs. Their study is at an early stage and it would not be surprising to see their importance grow in numerous diseases, particularly in cancer. Our identification here of such an RNA in lung cancer cells is one illustration. B2 seems especially interesting in that it can regulate apoptosis and cell proliferation by modulating HEF1. In addition, the fact that cytostatic treatments can induce B2 reinforces the interest of this new potential target in the development of anticancer treatments.
